LGK974 No Further a Mystery
Because permitted in 2014, tucidinostat was considered as a second-line and subsequent therapy for PTCL sufferers in China. Scientific trials and preclinical research in a number of hematological malignancies and solid tumors is in progress.The intention of the present period IIb examine was To guage the efficacy and basic safety of tucidinostat in